Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome - 28/03/23
Abstract |
Aims |
To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients.
Methods |
Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires.
Results |
MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: −1.7 mg/dL(± 13.5); ∆ metformin: − 2.5(± 23.9) mg/dL; ∆ DPP-4I: − 4.5(± 42.6); mg/dL ∆ GLP-1RA: − 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: − 0.1(± 0.7) %; ∆ DPP-4I: − 0.1(± 1.0) %; ∆ GLP-1RA: − 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: −0.8(± 1.6) kg/m2; ∆ metformin: − 0.8(± 1.5) kg/m2; ∆ DPP-4I: − 0.6(± 1.3) kg/m2; ∆ GLP-1RA: − 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: −2.8(± 5.2) cm; ∆ metformin: − 2.6(± 15.2) cm; ∆ DPP-4I: − 2.1(± 4.8) cm; ∆ GLP-1RA: − 2.4(± 4.1) cm.
Conclusion |
In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Patients treated with GLP-1RA and DPP-4I obtained a better glycemic profile, but anthropometric improvements were modest. |
• | Patients who decreased their energy intake the least at one year of the intervention were those treated with DPP-4I. |
• | The GLP-1RA participants had a higher systolic blood pressure reduction, compared to others. |
Abbreviations : BMI, DPP-4, DPP-4I, EMA, FDA, GIP, GLM, GLP-1, GLP-1RA, HbA1c, MetS, WC
Keywords : Metabolic syndrome, Glucagon-like peptide 1 agonists, GLP-1RA, 4-dipeptidyl peptidase inhibitors, DPP-4I
Plan
| ☆ | Clinical Trial Registry number: The trial was registered in 2014 at the International Standard Randomized Controlled Trial (ISRCT; ISRCTN89898870) with number 89898870. |
Vol 161
Article 114561- mai 2023 Retour au numéro
Article précédent
- Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model
- Rasha Abdelhady, Simona Cavalu, Sameh Saber, Rasha Elmowafy, Nesreen Elsayed Morsy, Samar Ibrahim, Mahmoud Said Ibrahim Abdeldaiem, Mervat Samy, Marwa A. Abd-Eldayem, Ahmed Shata, Rehab Mohamed Elgharabawy
- Molecular docking and anti-ulcerative potential of Cucumis (L. Inodorous) on ibuprofen induced gastric ulceration in male wistar animals
- Grace Adebayo-Gege, Zainab Shehu Uthman, Moses Dele Adams, Tarfa Florence, Danazumi Umar Haruna, Ngabea Murtala Audu, Hamidu Jabba Lawan, Ozegbe Queen, Onwuchekwa Chinedu, Ajibola Meraiyebu, Ojo Kafaru
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?